Durvalumab With or Without Olaparib as Maintenance Therapy After First-Line Treatment of Advanced and Recurrent Endometrial Cancer (DUO-E)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04269200 |
|
Recruitment Status :
Active, not recruiting
First Posted : February 13, 2020
Last Update Posted : March 5, 2024
|
Sponsor:
AstraZeneca
Collaborators:
The Gynecologic Oncology Group (GOG) Foundation Inc
The European Network for Gynaecological Oncological Trial groups (ENGOT)
Information provided by (Responsible Party):
AstraZeneca
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Brief Summary:
A study to assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Endometrial Neoplasms | Drug: olaparib Biological: durvalumab Drug: durvalumab placebo Drug: olaparib placebo Drug: Carboplatin Drug: Paclitaxel | Phase 3 |
This Phase III study will assess the efficacy and safety of durvalumab in combination with platinum-based chemotherapy (paclitaxel + carboplatin) followed by maintenance durvalumab with or without olaparib for patients with newly diagnosed advanced or recurrent endometrial cancer.
Target patient population: Adult female patients with histologically confirmed diagnosis of epithelial endometrial carcinoma (excluding sarcomas): newly diagnosed Stage III, newly diagnosed Stage IV, or recurrent endometrial cancer
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 805 participants |
| Allocation: | Randomized |
| Intervention Model: | Parallel Assignment |
| Intervention Model Description: | double-blind, placebo-controlled |
| Masking: | Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor) |
| Primary Purpose: | Treatment |
| Official Title: | A Randomised, Multicentre, Double-blind, Placebo-controlled, Phase III Study of First-line Carboplatin and Paclitaxel in Combination With Durvalumab, Followed by Maintenance Durvalumab With or Without Olaparib in Patients With Newly Diagnosed Advanced or Recurrent Endometrial Cancer (DUO-E) |
| Actual Study Start Date : | May 5, 2020 |
| Estimated Primary Completion Date : | March 5, 2025 |
| Estimated Study Completion Date : | March 5, 2025 |
Resource links provided by the National Library of Medicine
| Arm | Intervention/treatment |
|---|---|
|
Active Comparator: Arm A (control)
Platinum-based chemotherapy and durvalumab placebo followed by maintenance durvalumab placebo and olaparib placebo (tablets).
|
Drug: durvalumab placebo
Matching placebo for intravenous infusion Drug: olaparib placebo Placebo tablets to match olaparib Drug: Carboplatin Standard of care chemotherapy Drug: Paclitaxel Standard of care chemotherapy |
|
Experimental: Arm B (durvalumab+placebo)
Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib placebo
|
Biological: durvalumab
Durvalumab by intravenous infusion Drug: olaparib placebo Placebo tablets to match olaparib Drug: Carboplatin Standard of care chemotherapy Drug: Paclitaxel Standard of care chemotherapy |
|
Experimental: Arm C (durvalumab+olaparib)
Platinum-based chemotherapy and durvalumab followed by maintenance durvalumab and olaparib.
|
Drug: olaparib
Olaparib tablets Biological: durvalumab Durvalumab by intravenous infusion Drug: Carboplatin Standard of care chemotherapy Drug: Paclitaxel Standard of care chemotherapy |
Primary Outcome Measures :
- Progression Free Survival (PFS) for Arm B vs Arm A and Arm C vs Arm A [ Time Frame: Up to 4 years ]Defined as the time from randomisation until the date of objective disease progression (per RECIST 1.1 as assessed by investigator) or death (by any cause in the absence of progression)
Secondary Outcome Measures :
- Second Progression (PFS2) [ Time Frame: Up to 6 years ]Defined as the time from randomisation to the earliest of progression event subsequent to first subsequent therapy (assessed by the investigator per local standard clinical practice and may involve any of the following: objective radiological imaging, symptomatic progression), or death due to any cause
- Overall Survival (OS) [ Time Frame: Up to 6 years ]Defined as the time from randomisation to death due to any cause
- Objective Response Rate (ORR) [ Time Frame: Up to 4 years ]Defined as the proportion of patients with measurable disease at baseline who have confirmed complete response (CR) or partial response (PR) as determined by the Investigator at local site.
- Duration of response (DoR) [ Time Frame: Up to 4 years ]Defined as time from the date of first documented response until date of documented progression or death in the absence of disease progression
- Time to first subsequent therapy (TFST) [ Time Frame: Up to 6 years ]Defined as the time from randomisation to the earlier of start date of the first subsequent anti-cancer therapy after discontinuation of randomised treatment or death due to any cause
- Time to second subsequent therapy (TSST) [ Time Frame: Up to 6 years ]Defined as the time from randomisation to the earlier of start date of the second subsequent anti-cancer therapy after discontinuation of first subsequent treatment or death due to any cause.
- Time to discontinuation or death (TDT) [ Time Frame: Up to 6 years ]Defined as the time from randomisation to the earlier of the date of study treatment discontinuation or death.
- The pharmacokinetics (PK) of durvalumab will be determined after steady state doses [ Time Frame: Up to 4 years ]Determination of durvalumab concentration in serum
- Safety and tolerability of drugs by assessment of AEs/SAEs [ Time Frame: Up to 6 years ]Graded according to the National Cancer Institute (NCI CTCAE)
- The immunogenicity of durvalumab as determined by concentration of Anti-drug antibodies (ADA) to durvalumab [ Time Frame: Up to 4 years ]Determination concentration of Anti-drug antibodies (ADA) to durvalumab in serum
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 150 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | Female |
| Gender Based Eligibility: | Yes |
| Gender Eligibility Description: | Female subjects only |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Age ≥18 years at the time of screening and female.
- Histologically confirmed diagnosis of epithelial endometrial carcinoma. All histologies, including carcinosarcomas, will be allowed. Sarcomas will not be allowed.
-
Patient must have endometrial cancer in one of the following categories:
- Newly diagnosed Stage III disease (measurable disease per RECIST 1.1 following surgery or diagnostic biopsy),
- Newly diagnosed Stage IV disease (with or without disease following surgery or diagnostic biopsy)
- Recurrence of disease (measurable or non-measurable disease per RECIST 1.1) where the potential for cure by surgery alone or in combination is poor.
- Naïve to first line systemic anti-cancer treatment. For patients with recurrent disease only, prior systemic anti-cancer treatment is allowed only if it was administered in the adjuvant setting and there is at least 12 months from date of last dose of systemic anti-cancer treatment administered to date of subsequent relapse
- FPPE tumor sample must be available for MMR evaluation.
- Has Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 within 7 days of starting study treatment.
Exclusion Criteria:
- History of leptomeningeal carcinomatosis.
- Brain metastases or spinal cord compression.
- Prior treatment with PARP inhibitors.
- Any prior exposure to immune-mediated therapy, including (but not limited to) other anti CTLA-4, anti-PD-1, anti-PD-L1, or anti-programmed-cell-death ligand 2 (anti-PD-L2) antibodies, excluding therapeutic anticancer vaccines.
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04269200
Locations
Show 202 study locations
Sponsors and Collaborators
AstraZeneca
The Gynecologic Oncology Group (GOG) Foundation Inc
The European Network for Gynaecological Oncological Trial groups (ENGOT)
Investigators
| Principal Investigator: | Shannon N. Westin, MD, MPH, FACOG | The University of Texas MD Anderson Cancer Center |
| Responsible Party: | AstraZeneca |
| ClinicalTrials.gov Identifier: | NCT04269200 |
| Other Study ID Numbers: |
D9311C00001 GOG-3041 ( Other Identifier: Gynecologic Oncology Group(GOG) Foundation Inc ) ENGOT-EN10 ( Other Identifier: The European Network for Gynaecological Oncological Trial groups ) D9311C00001 ( Other Identifier: AZ DCode ) 2019-004112-60 ( EudraCT Number ) |
| First Posted: | February 13, 2020 Key Record Dates |
| Last Update Posted: | March 5, 2024 |
| Last Verified: | March 2024 |
| Individual Participant Data (IPD) Sharing Statement: | |
| Plan to Share IPD: | Yes |
| Plan Description: | Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
| Supporting Materials: |
Study Protocol Statistical Analysis Plan (SAP) |
| Time Frame: | AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
| Access Criteria: | When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure |
| URL: | https://astrazenecagroup-dt.pharmacm.com/DT/Home |
| Studies a U.S. FDA-regulated Drug Product: | Yes |
| Studies a U.S. FDA-regulated Device Product: | No |
Keywords provided by AstraZeneca:
|
Cancer of Endometrium Cancer of the Endometrium Carcinoma of Endometrium Endometrial Cancer |
Endometrial Carcinoma Endometrium Cancer Neoplasms, Endometrial |
Additional relevant MeSH terms:
|
Endometrial Neoplasms Neoplasms Uterine Neoplasms Genital Neoplasms, Female Urogenital Neoplasms Neoplasms by Site Uterine Diseases Genital Diseases, Female Female Urogenital Diseases Female Urogenital Diseases and Pregnancy Complications Urogenital Diseases Genital Diseases Paclitaxel Carboplatin |
Durvalumab Olaparib Antibodies, Monoclonal Antineoplastic Agents, Phytogenic Antineoplastic Agents Tubulin Modulators Antimitotic Agents Mitosis Modulators Molecular Mechanisms of Pharmacological Action Antineoplastic Agents, Immunological Immunologic Factors Physiological Effects of Drugs Poly(ADP-ribose) Polymerase Inhibitors Enzyme Inhibitors |